Journal Mobile Options
Table of Contents
Vol. 28, No. 3, 2010
Issue release date: October 2010
Dig Dis 2010;28:519–524
(DOI:10.1159/000320411)

Epstein-Barr Virus, Lymphoma Risk and the Potential Role of HIV Infection in IBD Patients Undergoing Immunosuppression

Weinstock D.M.
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Mass., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

For decades, lymphoma has been considered a dreaded and untoward complication of autoimmune disorders, including inflammatory bowel disease (IBD). Yet until recently, the data linking inflammatory bowel disease with an increased risk for lymphoma has been equivocal. With the publication of the CESAME trial in 2009, a greater understanding of lymphoma risk has begun to emerge. In this Falk Symposium paper, I discuss the available data from studies that interrogated the relationship between lymphoma and IBD, thiopurines and TNFα-directed agents. While recent data has clarified some aspects of lymphoma epidemiology in patients with IBD, causality and the mechanisms that underlie it remain very poorly understood.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Good RA: Relations between immunity and malignancy. Proc Natl Acad Sci USA 1972;69:1026–1032.
  2. Smith MA, Irving PM, Marinaki AM, Sanderson JD: Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 2010, E-pub ahead of print.
  3. Lakatos PL, Miheller P: Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? Curr Drug Targets 2010;11:179–186.
  4. Bewtra M, Lewis JD: Safety profile of IBD: lymphoma risks. Med Clin North Am 2010;94:93–113.
  5. Sokol H, Beaugerie L: Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009;58:1427–1436.
  6. Lenz G, Staudt LM: Aggressive lymphomas. N Engl J Med 2010;362:1417–1429.
  7. Jaffe ES, Harris NL, Stein H, Isaacson PG: Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008;112:4384–4399.
  8. Kutok JL, Wang F: Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006;1:375–404.
  9. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57–70.
  10. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151–3158.
  11. Smedby KE, Baecklund E, Askling J: Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15:2069–2077.
  12. Jones JL, Loftus EV Jr: Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007;13:1299–1307.
  13. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121–1125.
  14. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, et al: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617–1625.
  15. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A: Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006;37:539–546.
  16. Armstrong RG, West J, Card TR: Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010;105:1604–1609.
  17. Wolfe F, Michaud K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433–1439.
  18. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874–881.
  19. Kotlyar D, Blonski W, Porter DL, Mendizabal M, Lin MV, et al: Hepatosplenic T cell lymphoma and inflammatory bowel disease: a rare complication after long-term thiopurine exposure: case report and systematic review of the literature. Digestive Disease Week, Chicago, 2009, abstr. S1133.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50